Locilex

Locilex

Cytolex, MSI-78, pexiganan acetate Infectious disease A topical antibiotic for treating infected diabetic foot ulcers; Locilex is the first in a class of antibiotic/anti-infective magainins, derived from the skin secretions of the African clawed frog, which kill bacteria by attacking cell membranes. See Magainin. Note: It was deemed not approvable.
References in periodicals archive ?
NASDAQ: DPRX), a late stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.
para]]- Scientific Poster Presentation Highlights Design of Locilex Phase 3 Pivotal Trials in Mild DFI[[/para]]
She has been assigned to work on the SmithKline Beecham Locilex account.
Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.
Food and Drug Administration ("FDA") on a Special Protocol Assessment ("SPA") for an upcoming Phase 3 registration trial in mild infections of diabetic foot ulcers with Locilex (TM)(pexiganan acetate cream 1%), an antibiotic peptide formulated as a topical cream.
In a poster presentation entitled "In Vitro Activity of Pexiganan Tested Against Pathogens with Elevated MICs to Topical Antimicrobials," investigators stated that pexiganan, the active pharmaceutical ingredient in Locilex, demonstrated potent in vitro activity against a broad spectrum of Gram-positive and Gram-negative bacteria selected as having elevated MIC[sub.
Food and Drug Administration and Dipexium for evaluation of Locilex for the treatment of patients with mild infections of diabetic foot ulcers.
The additional capital will be available for general corporate purposes, including use to conduct a marketing launch of Locilex in the U.
Dipexium and its research collaborators, will present data on pexiganan, the active pharmaceutical ingredient in Locilex, that highlight pexiganan's activity against a broad spectrum of bacteria resistant to seven marketed or investigational topical antimicrobials.
para]]Planned Marketing Authorization Application for Locilex in Europe for treatment of patients with diabetic foot infection appropriate for topical therapy not expected to require any new clinical trials[[/para]]
para]]Scientific Poster Presentation Highlights Design of Locilex Phase 3 Pivotal Trials in Mild DFI[[/para]]
This additional capital enabled us to expand our team, initiate OneStep-1 and OneStep-2, our pivotal Phase 3 clinical trials for Locilex in mild infections of diabetic foot ulcers (Mild DFI), and complete DPX-110 and DPX-120, our two Phase 1 clinical trials.